CGオンコロジー
CG Oncology, Inc. Common stock
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.71 | $1M | -$57M |
| 2025 Q4 | -0.52 | $2M | -$36M |
| 2025 Q3 | -0.57 | $2M | -$39M |
| 2025 Q2 | -0.54 | $0 | -$28M |
| 2025 Q1 | -0.45 | $52,000 | -$29M |
| 2024 Q4 | -0.49 | $456,000 | -$21M |
| 2024 Q3 |
| -0.30 |
| $43,000 |
| -$16M |
| 2024 Q2 | -0.28 | $111,000 | -$16M |